Nusaïbah Ibrahimi

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet et al. · Nature Communications · 2022 · 113 citations · Full text

Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study

Cécile Charles, A. Bardet, Nusaïbah Ibrahimi et al. · Journal of Telemedicine and Telecare · 2021 · 39 citations

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients

Nicolas Chapuis, Nusaïbah Ibrahimi, Thibaut Belmondo et al. · EBioMedicine · 2022 · 35 citations · Full text

189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

B. Pistilli, Nusaïbah Ibrahimi, M. Lacroix-Triki et al. · ESMO Open · 2023 · 17 citations · Full text

Breast Oncology, Immunology, Pathology +16

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet et al. · 2021 · 12 citations · Full text